Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Ascierto, Paolo A

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. [electronic resource] - European journal of cancer (Oxford, England : 1990) 02 2020 - 33-44 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1879-0852

10.1016/j.ejca.2019.11.016 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Benzimidazoles--administration & dosage
Carbamates--administration & dosage
Diarrhea--chemically induced
Disease-Free Survival
Female
Humans
Male
Melanoma--drug therapy
Middle Aged
Mutation
Nausea--chemically induced
Outcome Assessment, Health Care--methods
Prognosis
Proto-Oncogene Proteins B-raf--genetics
Skin Neoplasms--drug therapy
Sulfonamides--administration & dosage
Vemurafenib--administration & dosage
Vomiting--chemically induced